

NHS South East Staffordshire & Seisdon Peninsula Clinical Commissioning Group (CCG) and Astellas Pharma Ltd Urology resource analysis and service redesign Pathway review: June 2014 – April 2015

Background

Across South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group (SES&SP CCG), there are initiatives and proposals to ensure patients with long term conditions are managed by general practice services. Whilst those with continence problems can be classed as long term conditions, it has been agreed that these patients would be best serviced by a dedicated specialist team in the community and not within general practice.

Analysis of available data (e.g. referral, prescribing, admissions) and interactions with stakeholders involved in the provision of lower urinary tract symptoms (LUTS) will provide evidence which can provide a baseline understanding of current performance prior to any redesign.

Through analysis of all the urology services available, the precise offering of each service will be understood and a clear picture of the resource use at practice level can be built. This will allow the identification of areas where efficiency gains can be made. Decisions on service redesign will be made by local commissioners based on the results of the analysis.

Project

Patient	<ul style="list-style-type: none"> • Improve the quality and responsiveness of care for patients with LUTS in line with NICE guidance and the patient's quality of life and personal treatment goals • Create an integrated service for management of LUTS patients
NHS	<ul style="list-style-type: none"> • Identify areas where there is potential to improve efficiency; cost effectiveness, and/or quality which will inform service redesign • Make recommendations on service redesign to assist local commissioners • Improve coordination, understanding and communications between primary and secondary care
Astellas	<ul style="list-style-type: none"> • Demonstration of how Joint Working between Astellas and SES&SP CCG has improved the patient pathway for urology and led to a better patient experience • Increased use of appropriate urology medicines, including Astellas medicines, in line with NICE guidelines